Drugs

Papers
(The H4-Index of Drugs is 60. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Arimoclomol: First Approval411
Iruplinalkib: First Approval373
Empagliflozin: A Review in Symptomatic Chronic Heart Failure283
Effectiveness of Interventions to Reduce Opioid Use After Orthopaedic Surgery: A Systematic Review of Randomised Controlled Trials265
Epcoritamab: First Approval212
Tirzepatide: First Approval189
Olutasidenib: First Approval185
Pimitespib: First Approval162
Alcohol-Associated Liver Disease: Evolving Concepts and Treatments153
New Therapies on the Horizon for Primary Biliary Cholangitis131
Tebentafusp: First Approval127
Teprotumumab: A Review in Thyroid Eye Disease116
Imetelstat: First Approval112
Bone Fragility in Diabetes and its Management: A Narrative Review103
Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis99
Long-Term Efficacy and Tolerability of PCSK9 Targeted Therapy: A Review of the Literature98
Mirvetuximab Soravtansine: First Approval97
Coronary Microvascular Dysfunction in Patients with Non-Obstructive Coronary Arteries: Current Gaps and Future Directions95
Vorasidenib: First Approval94
Correction: Vorasidenib: First Approval91
Vosoritide: First Approval89
Aprocitentan: First Approval89
Tunlametinib: First Approval87
Crovalimab: First Approval85
Zanidatamab: First Approval85
Difelikefalin: First Approval81
Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria81
Etrasimod: First Approval81
Tamoxifen Dose De-Escalation: An Effective Strategy for Reducing Adverse Effects?80
Avalglucosidase alfa: First Approval79
Ocrelizumab: A Review in Multiple Sclerosis79
Contemporary Management of Dyslipidemia79
Savolitinib: First Approval77
Bexagliflozin: First Approval76
Beremagene Geperpavec: First Approval75
Dimdazenil: First Approval74
Correction: Iptacopan: First Approval74
Correction to: Interchangeability of Biosimilars: Overcoming the Final Hurdles72
Correction to: Benefits and Harms of ‘Smart Drugs’ (Nootropics) in Healthy Individuals72
Correction to: Lotilaner Ophthalmic Solution 0.25%: First Approval71
Correction to: Valemetostat Tosilate: First Approval70
Correction: Lumasiran: A Review in Primary Hyperoxaluria Type 170
Correction to: Birch Bark Extract: A Review in Epidermolysis Bullosa70
Correction to: Netupitant/Palonosetron: A Review in Chemotherapy-Induced Nausea and Vomiting69
Correction: Vonoprazan: A Review in Helicobacter pylori Infection68
Zastaprazan: First Approval67
Correction to: Fostamatinib: A Review in Chronic Immune Thrombocytopenia67
Correction to: Secukinumab: A Review in Psoriatic Arthritis66
Correction to: Darinaparsin: First Approval66
Relugolix/Estradiol/Norethisterone Acetate: A Review in Endometriosis-Associated Pain66
Bimekizumab for the Treatment of Psoriasis65
First-line Immune Checkpoint Inhibitor Combinations in Metastatic Renal Cell Carcinoma: Where Are We Going, Where Have We Been?65
New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical Practice65
Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease63
Pharmacological Treatment for Pedophilic Disorder and Compulsive Sexual Behavior Disorder: A Review63
New Topical Therapies in Development for Atopic Dermatitis63
The Effect of Oral Antidiabetic Drugs on Improving the Endocrine and Metabolic States in Women with Polycystic Ovary Syndrome: A Systematic Review and Network Meta-analysis62
Eye Involvement and Management in Inherited Epidermolysis Bullosa62
Update on the Application of Monoclonal Antibody Therapy in Primary Membranous Nephropathy61
Correction: New Pharmacologic Approaches to the Treatment of Bipolar Depression60
Spesolimab for the Treatment of Generalized Pustular Psoriasis60
Asthma and Cardiovascular Diseases: Navigating Mutual Pharmacological Interferences60
The Effect of Biological Treatment on Fatigue in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis60
0.30736303329468